Combination of 7-Hydroxycoumarin (cas 93-35-6) in a platinum(IV) complex derived from cisplatin enhanced cytotoxicity with multiple mechanisms of action

Add time:07/18/2019    Source:sciencedirect.com

A novel compound, Cou-platin, composed of 7-Hydroxycoumarin (cas 93-35-6) and a platinum(IV) moiety derived from cisplatin was designed and synthesized. Significantly, Cou-platin exhibited more potent in vitro antitumor activity against all tested cancer cell lines than that of cisplatin, which was mainly attributed to the liberation of cisplatin and 7-hydroxycoumarin upon reduction with a biomolecular agent. Besides, cellular accumulation of Cou-platin was dramatically increased among several cancer cells in contrast to cisplatin. Flow cytometry study revealed that Cou-platin arrested cell cycle at G2 phase and induced cell apoptosis. Western blots results indicated that it not only activated cell apoptosis pathway, but also inhibited extracellular regulated protein kinases/mitogen-activated protein kinase pathway. In vivo tests showed that Cou-platin, at equimolar dose to cisplatin, could inhibit tumor growth in nude mouse HCT116 tumor xenograft models almost as cisplatin and oxaliplatin, but with less toxicity.

We also recommend Trading Suppliers and Manufacturers of 7-Hydroxycoumarin (cas 93-35-6). Pls Click Website Link as below: cas 93-35-6 suppliers

Prev:Structural investigation of Cu(II) complexes with dibromo 7-Hydroxycoumarin (cas 93-35-6) derivatives using methodology based on XAS
Next:Hepatoprotective effect of 7-Hydroxycoumarin (cas 93-35-6) against Methyl glyoxal toxicity via activation of Nrf2)